表紙
市場調査レポート

Zedira GmbHの製品パイプライン分析

Zedira GmbH - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 318940
出版日 ページ情報 英文 29 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.06円で換算しております。
Back to Top
Zedira GmbHの製品パイプライン分析 Zedira GmbH - Product Pipeline Review - 2015
出版日: 2015年12月16日 ページ情報: 英文 29 Pages
概要

Zedira GmbHはバイオファーマシューティカル企業で、研究開発および診断用試薬の製造・販売や、新薬候補物質の開発などを行っています。同社製品のトランスグルタミナーゼは生理学的プロセスの研究において数多く利用されています。

当レポートでは、Zedira GmbHにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

Zedira GmbHの基本情報

  • Zedira GmbHの概要
  • 主要情報
  • 企業情報

Zedira GmbH:R&Dの概要

  • 主な治療範囲

Zedira GmbH:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • アウトライセンス製品
    • アウトライセンス製品/併用療法モダリティ

Zedira GmbH:パイプライン製品の概況

  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ
  • 開発段階が不明の製品
    • 開発段階が不明の製品/併用療法モダリティ

Zedira GmbH:薬剤プロファイル

  • ZED-101
  • ZED-1098
  • ZED-1219
  • ZED-1301
  • ZED-754
  • Small Molecules to Inhibit Factor XIII for Thrombosis

Zedira GmbH:パイプライン分析

Zedira GmbH:本社と子会社の所在地

  • 本社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07864CDB

Summary

Global Markets Direct's, 'Zedira GmbH - Product Pipeline Review - 2015', provides an overview of the Zedira GmbH's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Zedira GmbH's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Zedira GmbH including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Zedira GmbH's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Zedira GmbH's pipeline products

Reasons to buy

  • Evaluate Zedira GmbH's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Zedira GmbH in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Zedira GmbH's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Zedira GmbH and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Zedira GmbH
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Zedira GmbH and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Zedira GmbH Snapshot
    • Zedira GmbH Overview
    • Key Information
    • Key Facts
  • Zedira GmbH - Research and Development Overview
    • Key Therapeutic Areas
  • Zedira GmbH - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Zedira GmbH - Pipeline Products Glance
    • Zedira GmbH - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Zedira GmbH - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
    • Zedira GmbH - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • Zedira GmbH - Drug Profiles
    • ZED-1227
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Factor XIII for Thrombosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZED-101
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZED-1098
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZED-1219
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZED-1301
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZED-754
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Zedira GmbH - Pipeline Analysis
    • Zedira GmbH - Pipeline Products by Target
    • Zedira GmbH - Pipeline Products by Molecule Type
    • Zedira GmbH - Pipeline Products by Mechanism of Action
  • Zedira GmbH - Recent Pipeline Updates
  • Zedira GmbH - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Zedira GmbH, Key Information
  • Zedira GmbH, Key Facts
  • Zedira GmbH - Pipeline by Indication, 2015
  • Zedira GmbH - Pipeline by Stage of Development, 2015
  • Zedira GmbH - Monotherapy Products in Pipeline, 2015
  • Zedira GmbH - Out-Licensed Products in Pipeline, 2015
  • Zedira GmbH - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Zedira GmbH - Phase I, 2015
  • Zedira GmbH - Preclinical, 2015
  • Zedira GmbH - Discovery, 2015
  • Zedira GmbH - Unknown, 2015
  • Zedira GmbH - Pipeline by Target, 2015
  • Zedira GmbH - Pipeline by Molecule Type, 2015
  • Zedira GmbH - Pipeline Products by Mechanism of Action, 2015
  • Zedira GmbH - Recent Pipeline Updates, 2015

List of Figures

  • Zedira GmbH - Pipeline by Top 10 Indication, 2015
  • Zedira GmbH - Pipeline by Stage of Development, 2015
  • Zedira GmbH - Monotherapy Products in Pipeline, 2015
  • Zedira GmbH - Pipeline by Top 10 Target, 2015
  • Zedira GmbH - Pipeline by Top 10 Molecule Type, 2015
  • Zedira GmbH - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top